Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19

DOI 機関リポジトリ HANDLE Web Site PubMed 参考文献6件 オープンアクセス
  • Nakamura Hideta
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Miyagi Kazuya
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Otsuki Mariko
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Higure Yuuri
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Nishiyama Naoya
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Kinjo Takeshi
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Nakamatsu Masashi
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Haranaga Shusaku
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Tateyama Masao
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan
  • Fujita Jiro
    Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan

この論文をさがす

抄録

<p>Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor. </p>

収録刊行物

  • Internal Medicine

    Internal Medicine 59 (22), 2945-2949, 2020-11-15

    一般社団法人 日本内科学会

参考文献 (6)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ